UOC
MDGL icon

UBS O'Connor’s Madrigal Pharmaceuticals MDGL Stock Holding History

UBS O'Connor’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14,821
Closed -$4.14M – 312
2018
Q2 		$4.14M Buy
+14,821
New +$2.6M 0.08% 123
2015
Q2 		– Sell
-28,571
Closed -$1.94M – 880
2015
Q1 		$1.94M Buy
+28,571
New +$2.45M 0.02% 424

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS O'Connor's MDGL Position: Q3 2018 in Review

UBS O'Connor sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2018, closing a stake of 14,821 shares — an estimated $4.14M sold.

UBS O'Connor first reported a position in MDGL in Q1 2015 and held it in 2 quarters. The position peaked at $4.14M in Q2 2018. 156 funds tracked by Wall St. Rank hold MDGL as of Q3 2018.

  • UBS O'Connor reported no remaining Madrigal Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • UBS O'Connor sold 14,821 Madrigal Pharmaceuticals shares in Q3 2018, an estimated $4.14M.
  • UBS O'Connor first reported a position in Madrigal Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • UBS O'Connor's Madrigal Pharmaceuticals position peaked at $4.14M in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2018.

Based on UBS O'Connor's 13F filing for Q3 2018, filed 14 Nov 2018.